- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Marconi to distribute Norland bone densitometers
The Health Care Products (HCP) division of Marconi Medical Systems has signed a one-year agreement for North American distribution of bone measurement systems made by Norland Medical Systems.With the agreement, Marconi becomes the second major
The Health Care Products (HCP) division of Marconi Medical Systems has signed a one-year agreement for North American distribution of bone measurement systems made by Norland Medical Systems.
With the agreement, Marconi becomes the second major multimodality vendor to offer a line of bone mineral densitometers. The first, GE Medical Systems, in 2000 acquired Lunar and its line of x-ray and ultrasound BMD products.
In November, Norland signed an agreement with Cooper Surgical to distribute Norland bone density measurement systems to physician and group practices providing ob/gyn services in the U.S. and Canada. The Marconi HCP agreement is exclusive to hospitals and imaging and mammography centers in North America.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
